181 related articles for article (PubMed ID: 32572153)
21. Usefulness and limitations of E-cadherin and β-catenin in the classification of breast carcinomas in situ with mixed pattern.
Gomes DS; Porto SS; Rocha RM; Gobbi H
Diagn Pathol; 2013 Jul; 8():114. PubMed ID: 23837653
[TBL] [Abstract][Full Text] [Related]
22. ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast.
Ping Z; Siegal GP; Harada S; Eltoum IE; Youssef M; Shen T; He J; Huang Y; Chen D; Li Y; Bland KI; Chang HR; Shen D
Oncotarget; 2016 Dec; 7(49):80655-80663. PubMed ID: 27811364
[TBL] [Abstract][Full Text] [Related]
23. Frequent E-cadherin gene inactivation by loss of heterozygosity in pleomorphic lobular carcinoma of the breast.
Palacios J; Sarrió D; García-Macias MC; Bryant B; Sobel ME; Merino MJ
Mod Pathol; 2003 Jul; 16(7):674-8. PubMed ID: 12861063
[TBL] [Abstract][Full Text] [Related]
24. Nonlobular Invasive Breast Carcinomas with Biallelic Pathogenic CDH1 Somatic Alterations: A Histologic, Immunophenotypic, and Genomic Characterization.
Derakhshan F; Da Cruz Paula A; Selenica P; da Silva EM; Grabenstetter A; Jalali S; Gazzo AM; Dopeso H; Marra A; Brown DN; Ross DS; Mandelker D; Razavi P; Chandarlapaty S; Wen HY; Brogi E; Zhang H; Weigelt B; Pareja F; Reis-Filho JS
Mod Pathol; 2024 Feb; 37(2):100375. PubMed ID: 37925055
[TBL] [Abstract][Full Text] [Related]
25. Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas.
Simpson PT; Reis-Filho JS; Lambros MB; Jones C; Steele D; Mackay A; Iravani M; Fenwick K; Dexter T; Jones A; Reid L; Da Silva L; Shin SJ; Hardisson D; Ashworth A; Schmitt FC; Palacios J; Lakhani SR
J Pathol; 2008 Jul; 215(3):231-44. PubMed ID: 18473330
[TBL] [Abstract][Full Text] [Related]
26. Invasive lobular carcinoma with extracellular mucin production and HER-2 overexpression: a case report and further case studies.
Yu J; Bhargava R; Dabbs DJ
Diagn Pathol; 2010 Jun; 5():36. PubMed ID: 20550696
[TBL] [Abstract][Full Text] [Related]
27. Disparate E-cadherin mutations in LCIS and associated invasive breast carcinomas.
Rieger-Christ KM; Pezza JA; Dugan JM; Braasch JW; Hughes KS; Summerhayes IC
Mol Pathol; 2001 Apr; 54(2):91-7. PubMed ID: 11322170
[TBL] [Abstract][Full Text] [Related]
28. Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions.
Sarrió D; Pérez-Mies B; Hardisson D; Moreno-Bueno G; Suárez A; Cano A; Martín-Pérez J; Gamallo C; Palacios J
Oncogene; 2004 Apr; 23(19):3272-83. PubMed ID: 15077190
[TBL] [Abstract][Full Text] [Related]
29. CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer.
Caldeira JR; Prando EC; Quevedo FC; Neto FA; Rainho CA; Rogatto SR
BMC Cancer; 2006 Mar; 6():48. PubMed ID: 16512896
[TBL] [Abstract][Full Text] [Related]
30. Expression of P-cadherin, but not E-cadherin or N-cadherin, relates to pathological and functional differentiation of breast carcinomas.
Kovács A; Dhillon J; Walker RA
Mol Pathol; 2003 Dec; 56(6):318-22. PubMed ID: 14645693
[TBL] [Abstract][Full Text] [Related]
31. E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis.
Vos CB; Cleton-Jansen AM; Berx G; de Leeuw WJ; ter Haar NT; van Roy F; Cornelisse CJ; Peterse JL; van de Vijver MJ
Br J Cancer; 1997; 76(9):1131-3. PubMed ID: 9365159
[TBL] [Abstract][Full Text] [Related]
32. Aberrant expression of E-cadherin in lobular carcinomas of the breast.
Da Silva L; Parry S; Reid L; Keith P; Waddell N; Kossai M; Clarke C; Lakhani SR; Simpson PT
Am J Surg Pathol; 2008 May; 32(5):773-83. PubMed ID: 18379416
[TBL] [Abstract][Full Text] [Related]
33. Lobular breast cancer: Clinical, molecular and morphological characteristics.
Christgen M; Steinemann D; Kühnle E; Länger F; Gluz O; Harbeck N; Kreipe H
Pathol Res Pract; 2016 Jul; 212(7):583-97. PubMed ID: 27233940
[TBL] [Abstract][Full Text] [Related]
34. Germline CDH1 mutations in bilateral lobular carcinoma in situ.
Petridis C; Shinomiya I; Kohut K; Gorman P; Caneppele M; Shah V; Troy M; Pinder SE; Hanby A; Tomlinson I; Trembath RC; Roylance R; Simpson MA; Sawyer EJ
Br J Cancer; 2014 Feb; 110(4):1053-7. PubMed ID: 24366306
[TBL] [Abstract][Full Text] [Related]
35. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas.
Moll R; Mitze M; Frixen UH; Birchmeier W
Am J Pathol; 1993 Dec; 143(6):1731-42. PubMed ID: 8256859
[TBL] [Abstract][Full Text] [Related]
36. E-cadherin clone 36 nuclear staining dictates adverse disease outcome in lobular breast cancer patients.
Lobo J; Petronilho S; Newell AH; Coach J; Harlow G; Cruz A; Lopes P; Antunes L; Bai I; Walker E; Henrique R
Mod Pathol; 2019 Nov; 32(11):1574-1586. PubMed ID: 31231125
[TBL] [Abstract][Full Text] [Related]
37. E-cadherin expression correlates with histologic type but not tumour grade in invasive breast cancer.
Nurismah MI; Noriah O; Suryati MY; Sharifah NA
Asian Pac J Cancer Prev; 2008; 9(4):699-702. PubMed ID: 19256762
[TBL] [Abstract][Full Text] [Related]
38. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast.
Droufakou S; Deshmane V; Roylance R; Hanby A; Tomlinson I; Hart IR
Int J Cancer; 2001 May; 92(3):404-8. PubMed ID: 11291078
[TBL] [Abstract][Full Text] [Related]
39. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain.
Berx G; Cleton-Jansen AM; Strumane K; de Leeuw WJ; Nollet F; van Roy F; Cornelisse C
Oncogene; 1996 Nov; 13(9):1919-25. PubMed ID: 8934538
[TBL] [Abstract][Full Text] [Related]
40. Oncogenic PIK3CA mutations in lobular breast cancer progression.
Christgen M; Noskowicz M; Schipper E; Christgen H; Heil C; Krech T; Länger F; Kreipe H; Lehmann U
Genes Chromosomes Cancer; 2013 Jan; 52(1):69-80. PubMed ID: 22997091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
